Comparative bioavailability study in dogs of self-emulsifying formulation of progesterone presented in a pellet and liquid form compared with an aqueous suspension of progesterone

Journal of Pharmaceutical Sciences

Volumn 93, Issue 6, 2004, Pages 1495-1502

  Tuleu, Catherine ^a   Newton, Michael ^a   Rose, Jayna ^b   Euler, Danielle ^b   Saklatvala, Robert ^c   Clarke, Ashley ^c   Booth, Steven ^c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Merck Sharp & Dohme Limited   (United Kingdom)

Author keywords

In vivo evaluation (dogs); Pellets; Progesterone; Self emulsifying systems (SES)

Indexed keywords

PROGESTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; EMULSION; IN VITRO STUDY; LIQUID; NONHUMAN; PELLET EXTRUSION; PROGESTERONE BLOOD LEVEL; RANDOMIZATION; SPHERONIZATION; SUSPENSION;

EID: 2642540226     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20068     Document Type: Article

References (28)

1. Pouton CW. 2000. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and "self-microemulsifying" drug delivery systems. Eur J Pharm Sci 11:S93-S98.
2. Amidon GL, Lennernäs H, Shah VP, Crison JRA. 1995. Theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
3. Constantinides PP. 1995. Lipid micro emulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res 12:1561-1572.
4. Nazzal S, Nutan M, Palamakula A, Shah R, Zaghoul AA, Khan MA. 2002. Optimization of a self-nanoemulsified tablet dosage form of Ubiquinone using response surface methodology: Effect of formulation ingredients. Int J Pharm 240:103-114.
5. Sethia S, Squillante E. 2001. Bioavailibility of Carbamazepine from self-emulsifying solid dispersion formulated by supercritical fluid technology. AAPS PharmSci 3(suppl):(http://www. aapspharmsci.org).
6. Clarke AP, Booth SW, Petersson J, Podczeck F, Newton JM. 2000. Pellet formulations containing self-emulsifying systems. AAPS PharmSci 31(suppl): (http://www.aapspharmsci.org).
7. Newton JM, Petersson J, Podczeck F, Clarke AP, Booth SW. 2001. The influence of formulation variables on the properties of pellets containing a self-emulsifying mixture. J Pharm Sci 90:987-995.
8. Attama AA, Nzeke IT, Nnamani PO, Adikwu CO. 2003. The use of solid self-emulsifying systems in the delivery of diclofenac. Int J Pharm 262:23-28.
9. Simon JA, Robinson DE, Andrews MC, Hildebrand JR, Rocci ML, Blake RE, Odgen GD. 1993. The absorption of oral micronized progesterone: The effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril 60:26-33.
10. McAuley JW, Kroboth FJ, Kroboth PD. 1996. Oral administration of micronised progesterone: A review and more experience. Pharmacotherapy 16:453-457.
11. Kincl FA, Ciaccio LA, Benagiano G. 1978. Increasing oral bioavailability of progesterone by formulation. J Steroid Biochem 9:83-84.
12. Maxson WS, Hargove JT. 1985. Bioavailability of oral micronised progesterone. Fertil Stertil 44:622-626.
13. De Lignières B. 1999. Oral micronized progesterone. Clin Ther 21:41-60.
14. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. 1992. Self-emulsifying drug delivery systems: Formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm Res 9:87-93.
15. Shah NH, Carjaval MT, Patel CI, Infeld MH, Malick AW. 1994. Self-emulsifying drug delivery systems with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 106:15-23.
16. Gershanik T, Benita S. 1996. Positively charged self-emulsifying oil formulation for improving oral bioavailibility of progesterone. Pharm Dev Technol 1:147-157.
17. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. 1998. Formulation design and bioavailibility assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm 167:155-164.
18. Kim JY, Ku YS. 2000. Enhanced absorption of indomethacin after oral or rectal administration of a self-emulsifying system containing indometacin to rats. Int J Pharm 194:81-89.
19. Julianto T, Yuen KH, Noor AM. 2000. Improved bioavailibility of vitamin E with self-emulsifying formulation. Int J Pharm 200:53-57.
20. Kommurut R, Gurley B, Khan MA, Reddy IK. 2001. Self-emulsifying drug delivery systems of coenzyme Q10: Formulation development and bioavailibility assessment. Int J Pharm 212:233-246.
21. Pouton CW. 1999. Key issues when formulating hydrophobic drugs with lipids. Bull Tech Gattefosse No. 92, pp 41-49.
22. http://www.ncbi.nlm.nih.gov/PubMed/.
23. Perez-Victorias FJ, Conseil G, Munoz-Martinez F, Perez-Victoria JM, Dayan G, Marsaud V, Castanys S, Gamarro F, Renoir JM, Di Pietro A. 2003. RU49953: A non-hormonal steroid derivative that potently inhibits P-glycoprotein and reverts cellular multidrug resistance. Cell Mol Life Sci 60:526-535.
24. Ushigome F, Takanaga H, Matsuo H, Yanai S, Tsukimori K, Nakano H, Uchiumi T, Nakamura T, Kuwano M, Ohtani H, Sawada Y. 2000. Human placental transport of vinblastine, vincristine, digoxin and progesterone: Contribution of P-glycoprotein. Eur J Pharmacol 408:1-10.
25. Lo YL, Hsu CY, Huang JD. 1998. Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line. Anticancer Res 18:3005-3009.
26. Zhang H, Yao M, Morrison RA, Chong S. 2003. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 26:768-772.
27. Porter CJ, Charman WN. 2001. Intestinal lymphatic drug transport: an update. Adv Drug Del Rev 50:61-80.
28. Porter CJH, Charman WN. 2001. In vitro assessment of oral lipid based formulation. Adv Drug Del Rev 50(suppl 1):S127-S147.